HLB liver cancer new drug fails to receive US approval again... FDA "Chinese manufacturing facilities need to be supplemented" (comprehensive)
⚡ Quick Summary
(Seoul = Yonhap News) Reporter Park Sang-hyun = The U.S.
(Seoul = Yonhap News) Reporter Park Sang-hyun = The U.S. product approval for the liver cancer drug 'rivoceranib' promoted by HLB [028300] was once again rejected.
